Results: Among the 64 HIV patients coinfected with HBV, seven were seropositive for HDV (10.9%). There were no statistically significant differences in risk factors for acquiring HIV infection. During a median observation period of 27.8 months, the adjusted hazard ratio of HDV and HBV genotype (type B vs. non-type B) on hepatitis flare-ups were 62.132 (p Z 0.04) and 0.028 (p Z 0.01), respectively. All seven patients had genotype II and were HDV viremic. The phylogenetic tree analysis and clinical history evaluation did not identify any clusters of HDV infection. Conclusion: HDV infection resulted in higher rate of hepatitis flare-ups, but it did not have a statistical significance on HIV progression and immunological response to HAART. Whether higher rate of HDV viremia has worse impact on the hepatic outcomes requires further investigation.
eHBV coinfection patients in southern Taiwan remains uncertain. Methods: In this cohort study, a total of 64 HIV patients coinfected with HBV were identified between January 1, 2009 and May 30, 2012. The seroprevalence of anti-HDV antibodies, HDV genotyping, clinical manifestations and hepatic outcomes were compared between the patients with and without HDV coinfection, and laboratory examinations and hepatic outcomes were recorded.
Introduction
Viral hepatitis is a disease that contributes to abnormalities of liver function in HIV-infected patients. In the era of highly active antiretroviral therapy (HAART), liver damage caused by chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is the most common noneAIDSrelated cause of death in HIV-infected patients, especially those with a lower CD4 cell count. 1 However, in hepatitis B surface antigen (HBsAg)-positive HIV-infected patients, coinfection with hepatitis d virus (HDV) further leads to exacerbation and rapid progression of chronic liver disease, and consequently worse hepatic outcomes. 2e4 The prevalence of chronic HBV infection in general population is 15e20% in Taiwan, 5 and the prevalence of HDV coinfection in HBV-infected patients is estimated to be 5e8%. 6 In comparison, the prevalence of HBV infection in HIV-infected patients is estimated to be 11.5e21.7%. 7, 8 However, HIV-infected patients are at a higher risk of acquiring HDV due to parenteral and sexual routes of transmission, and the overall prevalence of HDV infection in HIVeHBV-coinfected patients has been reported to range from 14.5% to 43.9% in Taiwan. 3, 4, 7, 9 Sheng et al 3 reported the epidemiology and impact of HDV on hepatic outcomes, and virologic and immunological responses to HAART in HIVeHBV-coinfected patients in northern Taiwan. However, the epidemiology and impact of HDV infection in HIVeHBV-coinfected patients in southern Taiwan remains uncertain. We therefore conducted this prospective cohort study to investigate the epidemiology, hepatic events, and virologic responses to HAART in HBVeHIV coinfected patients in a medical center in southern Taiwan.
Methods Patients
This prospective cohort study was conducted in Kaohsiung Veterans General Hospital from January 2009 to May 2012. During this period, all of the HIV-infected patients who were seropositive for HBsAg were included. The minimum follow-up time was 6 months. Each patient underwent tests for hepatitis A IgG, hepatitis B e-antigen, antibodies to hepatitis B e-antigen, and antibodies to hepatitis C and hepatitis D when they were enrolled.
Serologic tests for hepatotropic viruses, CD4, and viral load measurement
HBsAg and anti-HDV antibodies were determined using an HBsAg radioimmunoassay, and an AUSAB-EIA kit (ARCHITECT i2000SR; Abbott Laboratories, Abbott Park, IL, USA), respectively. Anti-HCV antibodies were determined using an anti-HCV EIA kit (ARCHITECT i1000SR; Abbott Laboratories).
The plasma HIV RNA load and CD4 cell counts were quantified using a Cobas Amplicor HIV-1 monitor test, version 1.5 (Roche Diagnostics Corporation, Indianapolis, IN, USA) and FACSFlow (Becton Dickinson and Company, Franklin Lakes, NJ, USA), respectively.
Polymerase chain reaction

HBV
The first primer pair used for polymerase chain reaction (PCR) for HBV was POLHB1F (5 0 -CCT GCT GGT GGC TCC AGT T-3 0 ) and POLHB2R (5 0 -CRT CAG CAA ACA CTT GRC-3 0 ). The amplification conditions were 40 cycles at 94 C for 1 minute, 60 C for 1 minute, 72 C for 2 minutes, and a final extension at 72 C for 10 minutes. A 2-mL aliquot of the firstround PCR product was used for the second-round PCR, for which the conditions were the same as the first round. The second primer pair used was POLHB3F (5 0 -CTC GTG GTG GAC TTC TCT C-3 0 ) and POLHB4R (5 0 -GCA AAN CCC MAA AGR CCC AC-3 0 ). The expected size of the PCR product was 729 bp, and the PCR results were visualized by gel electrophoresis.
HDV
The first primer pair used was HDV850 (5 0 -CGG ATG CCC AGG TCG GAC C-3 0 ) and HDV1380 (5 0 -GGA GCW CCC CCG GCG AAG A-3 0 ). The amplification conditions were 30 cycles at 94 C for 30 seconds, 55 C for 1 minute, 72 C for 2 minutes, and a final extension at 72 C for 7 minutes. A 1-mL aliquot of the first-round PCR product was used for the second-round PCR, for which the conditions were the same as the first round. The second primer pair used was HDV856 (5 0 -AGG TGG AGA TGC CAT GCC GAC-3 0 ) and HDV1275 (5 0 -GGA YCA CCG AAG AAG GAA GGC C-3 0 ). The expected size of the PCR product was 419 bp and the PCR results were visualized by gel electrophoresis.
Sequence analysis
HBV
Sequencing of HBV was performed on the automated ABI Prism 3130 instrument, by using BigDye terminator cycle sequencing kit (Applied Biosystems, Warrington, Cheshire, UK). The primers used for the sequencing reaction were the same as those used for the second round of PCR; the sequencing cycling conditions were denaturation 2 minutes at 95 C, then 25 cycles of 10 seconds at 96 C, 5 minutes at 55 C, 3 minutes at 60 C. 10 To define HBV genotype, the pol sequences obtained by sequencing are compared to GenBank reference sequences by Basic Local Alignment Search Tool (BLAST) search analysis.
HDV
The sequences were aligned with the Clustal W program in the Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0 (Manufacturer: Megasoftware.net, Arizona, USA), with minor manual adjustments.
The phylogenetic trees were constructed by the neighbor-joining method based on the Kimura 2-parameter distance matrix in the MEGA software. Bootstrap values >700 of 1000 replicates were considered significant.
Clinical follow-up and assessment of hepatic outcomes
Serum VDRL, aminotransferase, bilirubin levels, CD4 cell count, and HIV-plasma viral load were determined regularly every 3e6 months. Abdominal sonography was performed every 6e12 months during follow-up or when clinically indicated at the discretion of the in-charge physician. Those who had abnormal findings on abdominal sonography were further investigated with abdominal computed tomography (CT). The virologic response to antiretroviral therapy was assessed by the HIV-plasma viral load (PVL) every 3e4 months during follow-up and within 3 months of the end of the study. Virologic failure was defined as failure to achieve an undetectable HIV-PVL after 6 months of HAART. The immunological response was assessed by the increase in CD4 cell count from baseline to within 3 months of the end of the study.
Hepatitis flare was defined as 2-fold elevation in serum aspartate and alanine aminotransferase level without any other etiologies. Liver cirrhosis was considered positive if coarse echogenicity, an irregular liver surface, and splenomegaly were all detected in abdominal sonography or abdominal CT. A diagnosis of hepatocellular carcinoma was based on typical findings on dynamic liver CT or magnetic resonance imaging scanning with or without a-fetoprotein >200 ng/mL.
Statistical analysis
All statistical analyses were performed using SPSS software, version 12.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were compared using c 2 or Fisher exact test, and noncategorical variables were compared using the Manne Whitney U test. All tests were two-tailed, and p < 0.05 was considered significant.
The survival probabilities were estimated using the KaplaneMeier method.
A Cox proportional hazard model was used to compare the difference in hepatitis flare-up rate between the HDVnegative and HDV-positive groups.
Results
Patient profile
Over the 41-month study period, 7 of 64 (10.9%) HIVeHBV coinfected patients had serological evidence of HDV infection. The baseline demographic and clinical characteristic data are summarized in Table 1 . Men who have sex with men (MSM) and heterosexual behavior were the major risk factors for HIV in both the HDV-positive and HDVnegative groups (85.6% and 94.6%, respectively). There were no statistically significant differences regarding mean age, sex, risk factor for HIV, underlying disease, CD4 þ count, and HIV-PVL at baseline.
HBV genotype, baseline hepatitis B viral load, and hepatitis virus markers
The characteristics of HBV genotype, baseline hepatitis B viral load, and hepatitis virus markers are summarized in Table 2 . The distribution of HBV genotype in the HDV-positive patients was B (1/2, 50%) and C (1/2, 50%). The distribution of HBV genotype in the HDV-negative patients was as follows: B (38/41, 92.6%), C (2/41, 4.8%), and D (1/41, 2.4%). There were no statistically significant differences in HBV viral load at baseline (p Z 0.11) or in the other hepatitis viral markers. There were also no statistically significant differences in HBV viral load stratified by genotype at baseline (type B and nontype B, p Z 0.28 and p Z 0.65, respectively). All seropositive HDV patients exhibited detectable HDV viremia.
Hepatic outcomes and HBV viral load at end of the study
The HDV-positive patients had higher rates of hepatitis flare-ups and cirrhosis at the end of the study (Table 3 and Fig. 1 ) compared with the HDV-negative group. The adjusted hazard ratio of HDV and HBV genotype (type B vs. non-type B) on hepatitis flares were 62.132 (95% confidence interval, 1.14e3382.17, p Z 0.04) and 0.028 (95% confidence interval, 0.002e0.329, p Z 0.01), respectively (Table 4 ). There were no statistically significant differences in hepatocellular carcinoma (p Z 1.0), aspartate aminotransferase (p Z 0.16), alanine aminotransferase (p Z 0.49), total bilirubin (p Z 0.81), a-fetoprotein (p Z 0.17), and HBV viral load at the end of the study (p Z 0.80). There were also no statistically significant differences in HBV viral load stratified by genotype at the end of the study (type B and non-type B, p Z 0.59 and p Z 0.18, respectively). c HBeAg data at baseline were available for seven of the HIVeHBVeHDV-coinfected patients and 40 of the HIVeHBV-coinfected patients.
d HAV IgG data at baseline were available for five of the HIVeHBVeHDV-coinfected patients and 52 of the HIVeHBV-coinfected patients.
e HCV Ab data at baseline were available for seven of the HIVeHBVeHDV-coinfected patients and 56 of the HIVeHBV-coinfected patients. Data are presented as n (%) or median (range). HAV Z hepatitis A virus; HBeAg Z hepatitis B e-antigen.
Immunologic and virologic responses to HAART
Fifty-two patients received antiretroviral therapy during follow-up. The immunological and virologic responses to antiretroviral therapy are summarized in Table 5 . At the end of the study, hepatitis D virus had no statistically significant impact on the immunological and virologic responses to HAART. The median increase of CD4 ＋ cell count was 8 cells/mL and 118 cells/mL for the HDV-positive and HDV-negative groups, respectively (p Z 0.17). The virologic failure rates were 33.3% and 17.3% for the HDVpositive and HDV-negative groups, respectively (p Z 0.61); 71% of the HDV-positive and 58% of the HDVnegative patients had undetectable HIV-PVL (p Z 0.69) in the end of the study.
Mortality
Four patients died during follow-up. There was no statistically significant difference in mortality rate between the HDV-positive and HDV-negative groups (Table 5 and Fig. 2) . One HDV-positive patient died of multiple myeloma and the other three HDV-negative patients died from complications of liver cirrhosis.
HDV phylogenetic analysis
HDV RNA was detected in all of the seven patients who were tested positive for anti-HDV and had genotype II. The phylogenetic tree analysis did not identify any clusters (Fig. 3) .
Discussion
In this prospective study, we found a lower seroprevalence (7/64, 10.9%) of HDV infection in HIV-HBV coinfected patients, and all of the HDV seropositive patients had genotype II, detectable HDV-RNA, and higher rate of hepatitis flare-ups compared with HDV seronegative patients. a Image studies of hepatocellular carcinoma at the end of the study were available for five of the HIVeHBVeHDV-coinfected patients and 57 of the HIVeHBV-coinfected patients.
b HBV viral load data at the end of the study were available for five of the HIVeHBVeHDV-coinfected patients and 49 of the HIVeHBVcoinfected patients.
c Of the 54 patients who had available data for HBV viral load at the end of the study, 33 patients had HBV genotype B. d a-FP data at the end of the study were available for five of the HIVeHBVeHDV-coinfected patients and 29 of the HIVeHBV-coinfected patients. Data are presented as n (%), unless otherwise indicated. ALT Z alanine aminotransferase; ART Z antiretroviral therapy; AST Z aspartate aminotransferase. HDV can be transmitted via the parenteral route, sexual contact, and, rarely perinatal, transmission.
11 A very small inoculum parenterally is sufficient to transmit infection, 12 and parenteral route through exposure to infected blood is a more effective way of transmitting HDV infection than sexual contact whether with or without HIV infection. 4,9,13e17 In this study, MSM and heterosexual behavior are the major risk factors for acquiring HIV, with intravenous drug users (IDUs) only 6.3%, and it may result in lower seroprevalence of HDV infection in HIVeHBV coinfected patients in our study (10.9%) compared with previous studies (14.5e43.9%). 3e5,8 HDV has eight genotypes, and the distribution of genotypes has been found to vary across geographic regions. HDV genotype I is prevalent worldwide, whereas genotype II (previously termed genotype-2a) is found in the Far East. 18 The genotype of HDV has changed in Taiwan in the past 2 decades. Early studies reported that genotype II accounted for 85.4% of patients with HBV-HDV coinfection in 1995, 19 whereas Su et al 20 in 2006 reported that genotype I and genotype II accounted for 26.3% and 38.1% of cases, respectively. Chang et al 9 reported that genotype II (41%) and genotype IV (55.7%) were the two major genotypes in HIV-infected patients. In our study, HDV genotype II was the only genotype isolated. This difference in distribution of HDV genotype may result from the different populations studied. In further phylogenetic tree analysis and clinical history evaluation through detailed questionnaire, we did not identify any clusters of HDV infection, excluding the possibility of laboratory contamination and virus spreading among our patients. Different HDV genotypes may have an impact on the manifestation of disease progression, with HDV genotype II presenting with higher remission rate and milder outcomes than patients infected with HDV genotype I. 19, 20 There are three patterns of HDV infection: coinfection, superinfection, and a minor patternehelper independent latent infection, which has been reported in the liver transplant setting. 11 Coinfection often leads to eradication of both agents, whereas superinfection mostly evolves to HDV chronicity. Acute HBV/HDV coinfection is characterized by the presence of a high titer of IgM antibody to hepatitis B core antigen (IgM anti-HBc), antibodies that disappear in chronic HBV infection. 11 None of the seven HDV seropositive patients in our study were positive for IgM anti-HBc, and therefore they were all cases of superinfection. Superinfection of an individual with chronic HBV can cause severe acute hepatitis and up to 80% of infected patients progress to chronicity, which causes more rapid progression to liver cirrhosis and decompensated liver than HBV infection alone. 18, 21 In the present study, the finding of increased rate of hepatitis events in the HDV-positive group compared to the HDV-negative group is compatible with previous reports in HIV-infected patients.
3,4 Different HBV genotypes has an impact on the clinical and therapeutic outcome. In HBV-monoinfected patients, HBV genotype C is more closely associated with active liver disease and increased risk for HCC than infection with genotype B. 22 In comparison, in HIV-infected patients, HBV genotype B has a higher risk of hepatitis flares and liver-related death than HBV genotype C. 23 In our study, risk of hepatitis flare-ups was lower in HBV genotype B than in HBV genotype nontype B (hazard ratio, 0.028; p Z 0.01). However, only four of the 43 (9.3%) individuals were HBV genotype nontype B in our cohort study. Whether HBV genotype B in HIV-infected patients is associated with lower hepatitis flare-ups needs further investigation.
Anti-HDV antibody is not, in itself, diagnostic of persistent HDV infection, and it may represent a serological marker of previous HDV. Viremia is representative of persistent viral replication, which results in worse hepatic outcomes. The reported incidence of HDV viremia in HDV seropositive HIV-infected patients is 36.8e86.8%.
3,4,9 A higher risk of hepatitis flare-ups and death in patients with HDV viremia was reported by Sheng et al 3 in 2007. Schaper et al 24 reported that levels of HDV-RNA and HBV-DNA fluctuate, and longitudinal testing revealed circulating serum HDV-RNA in most anti-HDV patients. Although all of the HDVpositive patients in our study were HDV viremic, further quantitative longitudinal testing of the HDV-positive patient in our study may be needed to determine the impact of viremia on disease progression and hepatic outcomes.
There are several limitations to our study. First, only a small numbers of patients were included, especially in the HDV seropositive group. Second, only four of 64 individuals were IDU patients, and therefore our result cannot not be applied to the IDU population. Third, no patients underwent a liver biopsy and the diagnosis of liver cirrhosis depended on imaging findings rather than histological change. Therefore, the incidence of liver cirrhosis may have been underestimated. Fourth, among 14 patients who ever received tenofovir-based regimen during follow-up, 11 received nonetenofovir-based regimen initially and were then switched to the tenofovir-based regimen due to adverse effect of the initial regimen or virologic failure or an episode of hepatitis. Due to the small sample size and limitation of study design, further comparison of hepatitis events between tenofovir-based and nonetenofovir-based regimen may have bias. Finally, a median follow-up period of 27.8 months is too short to demonstrate the difference in mortality between HDV seropositive and HDV seronegative patients. However, our cohort disclosed a statistically significant difference in rate of hepatitis flare-ups even through a short period of follow-up.
In conclusion, in our prospective study conducted in a medical center in southern Taiwan, HDV infection resulted in higher rate of hepatitis flare-ups. However, it did not have a statistical significance on HIV progression and immunological response to HAART. Lower HDV seroprevalence rate and changing genotype of HDV with only genotype II isolated were also noted. Whether a higher rate of viremia has a worse impact on the hepatic outcome requires further investigation.
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